Blue Cross Blue Shield · Pediatric Targeted Therapy · US health-plan appeal rights

Pediatric Targeted Therapy denied for failing step therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Pediatric Targeted Therapy denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for pediatric targeted therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Tumor-Agnostic Targeted Therapy (Vitrakvi / Rozlytrek / Koselugo / Ojemda)

The Blue Cross Blue Shield angle on Pediatric Targeted Therapy

## Why BCBS Applies Step Therapy to Pediatric Targeted Therapy — and How to Appeal

Step-therapy (also called "fail-first") denials require a patient to try one or more alternative treatments before the plan will cover the requested agent. For pediatric targeted therapies, this policy is particularly fraught: targeted agents are often prescribed precisely because the child's tumor has a specific molecular alteration that makes conventional therapies less effective or inappropriate. Applying a generic step-therapy ladder designed for common conditions to a molecularly selected pediatric population frequently has no clinical basis.

### Why This Denial Is Appealable

Most states have step-therapy exception laws, and federal ERISA plans are subject to ERISA's full-and-fair-review requirement under §503. Grounds for exception include: (1) the required step-therapy agents are contraindicated or clinically inappropriate for this patient; (2) the patient already tried and failed the required agents; or (3) the targeted therapy is indicated by a biomarker or genomic finding that makes the step-therapy alternatives scientifically inapplicable.

### Federal Appeal Framework

Internal appeal: Submit within the deadline in your denial letter. For urgent pediatric oncology cases, always request expedited review — the insurer must respond within 72 hours.
External review (ACA §2719 / ERISA §503): After exhausting internal appeals, you may request independent external review. File within approximately 4 months of the final internal denial. An accredited IRO will review whether the step-therapy requirement is clinically appropriate for this specific patient.

### Documentation to Gather

1. Biomarker or genomic testing results — the lab report confirming the molecular target that makes this therapy the appropriate choice. 2. Prior-treatment history — dates, agents used, doses, duration, and documented outcomes for any treatments already tried. 3. Specialist's medical-necessity letter — explicitly addressing why each required step-therapy alternative is inappropriate, ineffective, or already failed for this child. 4. FDA labeling and relevant guideline reference — show that the targeted therapy is the labeled or guideline-supported treatment for this biomarker profile (citing the applicable pediatric oncology society guideline by organization, not by specific numbers). 5. Plan's step-therapy criteria — request the full written policy so you can address every requirement point by point.

### Criteria-Mapping Structure

Build a table with one row per step-therapy requirement. For each required prior agent, document either (a) the date tried, the outcome, and why it was inadequate, or (b) the clinical reason it cannot safely or appropriately be tried (referencing the prescriber's letter and the FDA label). For the genomic indication, map the lab result directly to the labeled indication.

### Practical Next Step

If the molecular target is one recognized in the FDA label, the prescriber's letter should state plainly that the step-therapy alternatives do not address the identified target and that requiring them would delay clinically indicated therapy. Pair this with a request for expedited review given the pediatric oncology context.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Pediatric Targeted Therapy

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.